Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill combo aims to boost prostate cancer cure rates

NCT ID NCT06130995

Recruiting now Disease control Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether taking two hormone-blocking pills—relugolix and enzalutamide—before and after standard radiation or surgery can help cure high-risk locally advanced prostate cancer. About 46 men will participate to first find a safe dose, then see if the combo shrinks tumors more effectively. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

relugolix and enzalutamide (hormone-blocking pills)

What this could lead to

If this combination works, it could improve the chance of curing high-risk prostate cancer and help patients live longer without the cancer returning.

What could go wrong

This is a very early Phase 1 trial with only 46 people, so the main goal is to find a safe dose. It is too soon to know if the combination actually improves cure rates or survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm, Residual Pathologic Complete Response prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANDROGEN DEPRIVATION THERAPY LOCALLY ADVANCED PROSTATE CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Stephenson Cancer Center at OU Health, University of Oklahoma Health Sciences Center (SCC-OUHSC)

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••